[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Preclinical Imaging (In-VIVO) Market by Modality (Optical Imaging, PET, SPECT, CT, MRI, ultrasound, Photoacoustic Imaging, Magnetic Particle Imaging), Reagent (Optical Imaging Reagents, Contrast Agents, PET Tracers, SPECT Probes) - Global Forecast to 2021

August 2016 | 165 pages | ID: PC4E5F81066EN
MarketsandMarkets

US$ 3,955.00 US$ 5,650.00 -30 %
Offer valid until March 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global preclinical imaging market is estimated to grow at a high CAGR of 6.2% during 2016-2021; and is expected to be valued at USD 910.4 million by 2021. Although the mature markets (North America and Europe) held large share of preclinical imaging market in 2015; Asia-Pacific region is poised to be the fastest growing region during next five years. Factors such as continuous government support for pharmaceutical and biotechnology R&D, increasing public-private investments to support radioisotope production, rising number of translational research activities, and evolving regulatory scenario across major Asian countries are propelling the growth of the preclinical imaging market in Asia-Pacific region.

Market growth in the global preclinical imaging market is mainly driven by factors such technological advancements in the field of molecular imaging, increasing market demand for non-invasive small animal imaging techniques, and growing number of public-private initiatives and funding to support preclinical researches. In addition, emerging markets (such as China and India) are offering new growth opportunities for preclinical imaging market players.

Geographically, North America is estimated to command the largest share of the global preclinical imaging market in 2016, followed by Europe. The large market share of the North American region can be attributed to the robust R&D infrastructure for life science researches, fast adoption of novel molecular imaging technologies, significant presence of pharmaceutical and biotechnology companies, and increasing preference of end users for multimodality systems. However, continued outsourcing of in-house preclinical studies to emerging countries by U.S.-based pharmaceutical and biotechnology companies and reduced R&D expenditure by the Canadian government to support research studies are negatively affecting the growth of the preclinical imaging market in this region.

The preclinical imaging market is fairly competitive, with a large number of global and local manufacturers of preclinical imaging solutions. PerkinElmer, Inc. (U.S.), Bruker Corporation (U.S.), and FUJIFILM Holding Corporation (Japan) were the top three players in the preclinical imaging market in 2015. These companies together accounted for a share of 63.2% of the global preclinical imaging market in 2015. New product launches and product enhancements; geographic expansions; and partnerships, agreements, and collaborations are the major strategies adopted by most of the market players to achieve growth in the preclinical imaging market.

Report Objective:

This report studies preclinical imaging market based on modality and reagents; utilized for the assessment of anatomical, physiological, and functional parameters at molecular and cellular levels in live animal models. These imaging systems and reagents are applied to visualize living animals during preclinical research studies in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications.

The report also studies, the factors (such as drivers, restraints, opportunities, and challenges) which affect the market growth in positive and negative manner. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the preclinical imaging market report analyzes the micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market.

Detailed Segmentation:

Preclinical Imaging Market, by Modality
  • Optical Imaging Systems
  • Bioluminescence/Fluorescence Imaging Systems
  • Standalone Fluorescence Imaging Systems
  • Optical + X-Ray/Optical + CT
  • Preclinical Nuclear Imaging Systems
  • Micro-PET Systems
  • Micro-SPECT Systems
  • Trimodality (SPECT/PET/CT) Systems
  • Micro-MRI Systems
  • Micro-Ultrasound Systems
  • Micro-CT Systems
  • Preclinical Photoacoustic Imaging Systems
  • Preclinical Magnetic Particle Imaging (MPI) Systems
Preclinical Imaging Market, by Reagents
  • Preclinical Optical Imaging Reagents
  • Bioluminescent Imaging Reagents
  • Fluorescent Imaging Reagents
  • Preclinical Nuclear Imaging Reagents
  • Preclinical PET Tracers
  • Preclinical SPECT Probes
  • Preclinical MRI Contrast Agents
  • Gadolinium-based Preclinical MRI Contrast Agents
  • Iron-based Preclinical MRI Contrast Agents
  • Manganese-based Preclinical MRI Contrast Agents
  • Preclinical Ultrasound Contrast Agents
  • Preclinical CT Contrast Agents
  • Iodine-based Preclinical CT Contrast Agents
  • Barium-based Preclinical CT Contrast Agents
  • Gold Nanoparticles
  • Gastrografin-based Preclinical CT Contrast Agents
Preclinical Imaging Market, by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Key Target Audience:
  • Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
  • Pharmaceutical and Biotechnology Companies
  • Preclinical Imaging Reagent Manufacturers and Suppliers
  • Contract Research Organizations (CROs)
  • Research and Development (R&D) Companies
  • Government Research Laboratories
  • Independent Research Laboratories
  • Government and Independent Regulatory Authorities
  • Market Research and Consulting Service Providers
  • Medical Research Laboratories
Academic Medical Institutes and Universities
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
    1.3.1.1 Preclinical imaging market segmentation
    1.3.1.2 Preclinical imaging systems market segmentation
    1.3.1.3 Preclinical imaging reagents market segmentation
  1.3.2 GEOGRAPHIC SCOPE
  1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 SECONDARY DATA
    2.1.1.1 Key data from secondary sources
  2.1.2 PRIMARY DATA
    2.1.2.1 Key data from primary sources
    2.1.2.2 Breakdown of primaries
2.2 MARKET SIZE ESTIMATION
    2.2.1.1 Bottom-up approach
    2.2.1.2 Top-down approach
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
3.4 CONCLUSION

4 PREMIUM INSIGHTS

4.1 GLOBAL PRECLINICAL IMAGING MARKET
4.2 PRECLINICAL IMAGING PRODUCTS MARKET SHARE, BY REGION (2016)
4.3 GLOBAL PRECLINICAL IMAGING SYSTEMS MARKET, BY MODALITY (2016–2021)
4.4 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET, BY TYPE (2016–2021)
4.5 PRECLINICAL IMAGING MARKET, BY REGION (2016 VS. 2021)

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
  5.2.1 KEY MARKET DRIVERS
    5.2.1.1 Technological advancements in the field of molecular imaging
    5.2.1.2 Increasing market demand for noninvasive small-animal imaging techniques
    5.2.1.3 Growing number of public-private initiatives and funding to support preclinical researches
  5.2.2 KEY MARKET RESTRAINTS
    5.2.2.1 Strict regulations governing preclinical research
    5.2.2.2 Significant installation and operational costs associated with preclinical imaging modalities
  5.2.3 KEY MARKET OPPORTUNITY
    5.2.3.1 Emerging markets to offer new growth opportunities
  5.2.4 KEY MARKET CHALLENGE
    5.2.4.1 Technological and procedural limitations associated with standalone preclinical imaging systems

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION
6.2 VALUE CHAIN ANALYSIS
6.3 SUPPLY CHAIN ANALYSIS
  6.3.1 KEY STAKEHOLDERS
  6.3.2 KEY INFLUENCERS
6.4 KEY INDUSTRY TREND
  6.4.1 ONGOING DEVELOPMENT OF HYBRID AND MULTI-MODALITY PRECLINICAL IMAGING SYSTEMS
6.5 PORTER’S FIVE FORCES ANALYSIS
  6.5.1 THREAT OF NEW ENTRANTS
  6.5.2 THREAT OF SUBSTITUTES
  6.5.3 BARGAINING POWER OF SUPPLIERS
  6.5.4 BARGAINING POWER OF BUYERS
  6.5.5 INTENSITY OF COMPETITIVE RIVALRY

7 GLOBAL PRECLINICAL IMAGING MARKET, BY MODALITY

7.1 INTRODUCTION
7.2 OPTICAL IMAGING SYSTEMS
  7.2.1 BIOLUMINESCENCE AND FLUORESCENCE IMAGING SYSTEMS
  7.2.2 (OPTICAL + X-RAY)/(OPTICAL + CT) IMAGING SYSTEMS
  7.2.3 STANDALONE FLUORESCENCE IMAGING SYSTEMS
7.3 NUCLEAR IMAGING SYSTEMS
  7.3.1 MICRO-PET SYSTEMS
    7.3.1.1 Standalone PET Systems
    7.3.1.2 PET/CT Systems
    7.3.1.3 PET/MRI Systems
  7.3.2 MICRO-SPECT SYSTEMS
    7.3.2.1 Standalone SPECT Systems
    7.3.2.2 SPECT/CT Systems
    7.3.2.3 SPECT/MRI Systems
  7.3.3 TRIMODALITY (SPECT/PET/CT) SYSTEMS
7.4 MICRO-MRI SYSTEMS
7.5 MICRO-ULTRASOUND SYSTEMS
7.6 MICRO-CT SYSTEMS
7.7 PHOTOACOUSTIC IMAGING SYSTEMS
7.8 MAGNETIC PARTICLE IMAGING (MPI) SYSTEMS

8 GLOBAL PRECLINICAL IMAGING MARKET, BY REAGENT

8.1 INTRODUCTION
8.2 PRECLINICAL OPTICAL IMAGING REAGENTS
  8.2.1 BIOLUMINESCENT IMAGING REAGENTS
    8.2.1.1 Luciferins
    8.2.1.2 Proluciferins
    8.2.1.3 Coelenterazine
    8.2.1.4 Other Bioluminescent Imaging Reagents
  8.2.2 FLUORESCENT IMAGING REAGENTS
    8.2.2.1 Green Fluorescent Proteins
    8.2.2.2 Red Fluorescent Proteins
    8.2.2.3 Infrared Dyes
    8.2.2.4 Other fluorescent imaging reagents
8.3 PRECLINICAL NUCLEAR IMAGING REAGENTS
  8.3.1 PRECLINICAL PET TRACERS
    8.3.1.1 Fluorine-18-based Preclinical PET Tracers
    8.3.1.2 Carbon-11-based Preclinical PET Tracers
    8.3.1.3 Copper-64-based Preclinical PET Tracers
    8.3.1.4 Other PET tracers
  8.3.2 PRECLINICAL SPECT PROBES
    8.3.2.1 Technetium-99m-based Preclinical SPECT Probes
    8.3.2.2 Iodine-131-based Preclinical SPECT Probes
    8.3.2.3 Gallium-67-based Preclinical SPECT Probes
    8.3.2.4 Thallium-201-based Preclinical SPECT Probes
    8.3.2.5 Other SPECT probes
8.4 PRECLINICAL MRI CONTRAST AGENTS
  8.4.1 GADOLINIUM-BASED PRECLINICAL CONTRAST AGENTS
  8.4.2 IRON-BASED PRECLINICAL CONTRAST AGENTS
  8.4.3 MANGANESE-BASED PRECLINICAL CONTRAST AGENTS
8.5 PRECLINICAL ULTRASOUND CONTRAST AGENTS
8.6 PRECLINICAL CT CONTRAST AGENTS
  8.6.1 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS
  8.6.2 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS
  8.6.3 GOLD NANOPARTICLES
  8.6.4 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS

9 PRECLINICAL IMAGING MARKET, BY REGION

9.1 INTRODUCTION
9.2 NORTH AMERICA
9.3 EUROPE
9.4 ASIA-PACIFIC
9.5 REST OF THE WORLD (ROW)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 MARKET SHARE ANALYSIS, BY KEY PLAYER, 2015
10.3 COMPETITIVE SCENARIO
  10.3.1 NEW PRODUCT LAUNCHES
  10.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
  10.3.3 GEOGRAPHICAL EXPANSIONS
  10.3.4 ACQUISITIONS

11 COMPANY PROFILES

(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

11.1 INTRODUCTION
  11.1.1 GEOGRAPHIC BENCHMARKING
11.2 PERKINELMER, INC.
11.3 BRUKER CORPORATION
11.4 FUJIFILM HOLDINGS CORPORATION
11.5 MEDISO LTD.
11.6 MILABS B.V.
11.7 MR SOLUTIONS LTD.
11.8 ASPECT IMAGING LTD.
11.9 LI-COR BIOSCIENCES, INC.
11.10 TRIFOIL IMAGING, INC.
11.11 MILTENYI BIOTEC GMBH

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

12 APPENDIX

12.1 INSIGHTS OF INDUSTRY EXPERTS
12.2 DISCUSSION GUIDE
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
12.5 AVAILABLE CUSTOMIZATIONS
12.6 RELATED REPORTS

LIST OF TABLES

Table 1 PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014–2021 (USD MILLION)
Table 2 GLOBAL OPTICAL IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 3 OPTICAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 4 BIOLUMINESCENCE AND FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 (USD MILLION)
Table 5 (OPTICAL + X-RAY)/(OPTICAL + CT) IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 (USD MILLION)
Table 6 STANDALONE FLUORESCENCE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2012–2014 (USD MILLION)
Table 7 GLOBAL NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 8 NUCLEAR IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 9 GLOBAL MICRO-PET SYSTEMS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 10 MICRO-PET SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 11 STANDALONE PET SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 12 PET/CT SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 13 PET/MRI SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 14 GLOBAL MICRO-SPECT SYSTEMS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 15 MICRO-SPECT SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 16 STANDALONE SPECT SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 17 SPECT/CT SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 18 SPECT/MRI SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 19 TRIMODALITY SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 20 MICRO-MRI SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 21 MICRO-ULTRASOUND SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 22 MICRO-CT SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 23 PHOTOACOUSTIC IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 24 MAGNETIC PARTICLE IMAGING SYSTEMS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 25 GLOBAL PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 26 GLOBAL PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 27 PRECLINICAL OPTICAL IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 28 GLOBAL PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 29 PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 30 PRECLINICAL LUCIFERINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 31 PRECLINICAL PROLUCIFERINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 32 PRECLINICAL COELENTERAZINE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 33 OTHER PRECLINICAL BIOLUMINESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 34 GLOBAL PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 35 PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 36 PRECLINICAL GREEN FLUORESCENT PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 37 PRECLINICAL RED FLUORESCENT PROTEINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 38 PRECLINICAL INFRARED DYES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 39 OTHER PRECLINICAL FLUORESCENT IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 40 GLOBAL PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 41 PRECLINICAL NUCLEAR IMAGING REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 42 GLOBAL PRECLINICAL PET TRACERS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 43 PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 44 FLUORINE-18-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 45 CARBON-11-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 46 COPPER-64-BASED PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 47 OTHER PRECLINICAL PET TRACERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 48 GLOBAL PRECLINICAL SPECT PROBES MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 49 PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 50 TECHNETIUM-99M-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 51 IODINE-131-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 52 GALLIUM-67-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 53 THALLIUM-201-BASED PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 54 OTHER PRECLINICAL SPECT PROBES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 55 GLOBAL PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 56 PRECLINICAL MRI CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 57 GADOLINIUM-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 58 IRON-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 59 MANGANESE-BASED PRECLINICAL CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 60 PRECLINICAL ULTRASOUND CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 61 GLOBAL PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 62 PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 63 IODINE-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 64 BARIUM-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 65 GOLD NANOPARTICLES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 66 GASTROGRAFIN-BASED PRECLINICAL CT CONTRAST AGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 67 GLOBAL PRECLINICAL IMAGING SYSTEMS AND REAGENTS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 68 NORTH AMERICA: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 69 NORTH AMERICA: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014–2021 (USD MILLION)
Table 70 NORTH AMERICA: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014-2021 (USD MILLION)
Table 71 EUROPE: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 72 EUROPE: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014–2021 (USD MILLION)
Table 73 EUROPE: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 74 ASIA-PACIFIC: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 75 ASIA-PACIFIC: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
Table 76 ASIA-PACIFIC: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 77 ROW: PRECLINICAL IMAGING MARKET SIZE, BY PRODUCT, 2014–2021 (USD MILLION)
Table 78 ROW: PRECLINICAL IMAGING SYSTEMS MARKET SIZE, BY MODALITY, 2014-2021 (USD MILLION)
Table 79 ROW: PRECLINICAL IMAGING REAGENTS MARKET SIZE, BY TYPE, 2014–2021 (USD MILLION)
Table 80 TOP NEW PRODUCT LAUNCHES, 2013–2016
Table 81 TOP AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013–2016
Table 82 TOP GEOGRAPHICAL EXPANSIONS, 2013–2016
Table 83 TOP ACQUISITIONS, 2013–2016

The report “Pre-Clinical Imaging (In-VIVO) Market by Systems and Reagents (Optical Imaging, Micro-PET, Micro-SPECT, Micro-MRI, Micro-ultrasound, Computed Tomography, Photo Acoustic Imaging, Magnetic Particle Imaging, Multimodality Imaging).

This report studies the global preclinical imaging market over the forecast period of 2014 to 2019. The market is expected to reach $797 million by 2019, at CAGR of 6.0% from 2014 to 2019.

Aspect Imaging (Israel), Biospace Lab S.A. (France), Bruker Corporation (U.S.), LI-COR Biosciences (U.S.), Mediso Ltd. (Hungary), MILabs B.V. (Netherlands), MR Solutions Ltd (U.K.), PerkinElmer, Inc. (U.S.), TriFoil Imaging (U.S.), and FUJIFILM VisualSonics, Inc. (Canada) are the key players operating in the global preclinical imaging systems and reagents market.

A number of factors such as technological advancements in molecular imaging modalities, rising adoption of multi-modality imaging systems in preclinical research studies, and growing acceptance of preclinical imaging in drug discovery and development processes are fuelling the demand of preclinical imaging systems and reagents. On the other hand, declining NIH budgets for medical science research studies and high implementation cost of sophisticated preclinical imaging systems are restricting the growth of the global preclinical imaging market.

As of 2014, North America holds the largest share of the global preclinical imaging market, followed by Europe. However, the Asia-Pacific market is expected to grow at the highest CAGR of 8.2% from 2014 to 2019. A number of factors, including rising R&D activities by big pharma and biotech companies in developing nations, increased government funding for development of pharmaceutical industry, and growing number of CROs in emerging markets are stimulating the growth of the preclinical imaging market in the Asia-Pacific region. However, challenges associated with the application of radioisotopes, such as short half-life of PET radioisotopes and high cost involved in the generation of these isotopes, restricts the demand for micro-PET systems in developing Asian countries.



More Publications